Key Highlights
- ADMA Biologics reported second-quarter 2026 Revenue of $124.4 million, up 2%, with GAAP Net Income of $37.8 million and a gross Margin of 69%.
- Its specialty product ASCENIV grew 24% to $102.9 million and drove margins, while the older BIVIGAM fell 49%.
- The company reiterated full-year 2026 guidance of $530-$560 million in revenue and is buying back shares; it joined the S&P SmallCap 600 in September 2024.
- The headline revenue growth of 2% masks a much larger shift underneath: one product is now carrying nearly all of the company's growth and margin story.
ADMA Biologics (NASDAQ:ADMA) makes medicines from human plasma, and a specialty immune-boosting product for vulnerable patients has become the company's dominant growth engine. Rising sales of that high-margin product lifted profits again in the second quarter, even as an older, lower-margin product in the same portfolio continued to decline sharply, a divergence that matters more than the modest headline revenue growth suggests.
Making and selling plasma-derived medicines is ADMA's business: the company is a vertically integrated maker of medicines derived from human blood plasma, collecting or sourcing plasma, processing it and Manufacturing immune globulin products used to treat patients with compromised immune systems who are vulnerable to infection.
Profits Driven by the Specialty Product
ADMA Biologics reported second-quarter 2026 revenue of $124.4 million, up 2% year on year, with GAAP net income of $37.8 million and a gross margin of 69%, a notably high figure for a specialty pharmaceutical manufacturer. The modest 2% top-line growth figure understates what actually happened within the portfolio: ASCENIV, the company's specialty immune globulin product, grew 24% to $102.9 million, now representing the large majority of total revenue, while BIVIGAM, an older product in the same immune globulin category, fell 49%.
The company reiterated full-year 2026 guidance of $530 million to $560 million in revenue, and it is actively buying back shares, a signal of confidence in its cash generation given the strong gross margin. ADMA was added to the S&P SmallCap 600 index in September 2024, a milestone reflecting its growth into a mid-sized, index-eligible company.
Why One Product Is Carrying the Story
The gap between ASCENIV's 24% growth and BIVIGAM's 49% decline is the real story beneath the quarter's modest 2% headline growth. ASCENIV is evidently the higher-margin, higher-demand product in ADMA's portfolio, and its rapid growth is what is driving both the revenue increase and the strong 69% gross margin, since a shift toward a higher-margin product mix improves overall profitability even when total revenue growth looks unremarkable.
BIVIGAM's steep decline, by contrast, suggests either competitive pressure, changing physician preference, or a deliberate shift in ADMA's own commercial focus toward ASCENIV. Whatever the specific cause, the practical effect is that ADMA's near-term financial performance now depends heavily on ASCENIV's continued growth trajectory rather than on the portfolio as a whole.
The Opportunity
If ASCENIV's growth continues at anywhere near its current 24% pace, it alone could drive continued revenue growth and margin expansion for ADMA even as BIVIGAM's contribution shrinks toward a smaller share of the business. The company's reiterated full-year guidance of $530 million to $560 million suggests management remains confident in that trajectory, and the strong 69% gross margin gives ADMA meaningful Cash Flow to fund both continued Investment in ASCENIV's commercial growth and share buybacks.
Plasma-derived immune globulin products serve a genuine, recurring medical need among immune-compromised patients, and as ASCENIV becomes an increasingly larger share of ADMA's revenue, the overall Business should become both larger and higher-margin, assuming the trend holds.
Risks
The central risk is concentration: with ASCENIV now representing the large majority of revenue and BIVIGAM in steep decline, ADMA's financial performance is increasingly dependent on a single product's continued growth. Any slowdown in ASCENIV's growth rate, whether from competition, manufacturing constraints, plasma Supply issues or reimbursement changes, would have an outsized effect on the company's overall results given how concentrated revenue has become.
Plasma-derived manufacturing is itself a complex, capital-intensive and tightly regulated process, dependent on adequate plasma supply and consistent manufacturing quality; any disruption to that supply chain would directly affect ADMA's ability to meet Demand for its now-dominant product.
The Real Growth Rate Is Hidden Inside the Portfolio, Not in the Headline
The things to watch are ASCENIV's growth rate in coming quarters, whether it can sustain something close to its current 24% pace; the trajectory of BIVIGAM, whether its decline stabilizes or continues; gross margin trends as the product mix continues shifting; and progress against the reiterated $530 million to $560 million full-year revenue guidance.
ADMA Biologics' modest 2% headline revenue growth conceals a much more significant underlying shift: one specialty product is now effectively carrying the company's growth and margin story while an older product fades. That concentration is both the source of ADMA's improving profitability and its principal near-term vulnerability.






Please wait processing your request...